These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35798841)

  • 21. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
    Spangler JB; Manzari MT; Rosalia EK; Chen TF; Wittrup KD
    J Mol Biol; 2012 Sep; 422(4):532-44. PubMed ID: 22706026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
    Lu Y; Liang K; Li X; Fan Z
    Mol Cancer; 2007 Oct; 6():63. PubMed ID: 17931419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Nishimura Y; Bereczky B; Ono M
    Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain.
    Opresko LK; Chang CP; Will BH; Burke PM; Gill GN; Wiley HS
    J Biol Chem; 1995 Mar; 270(9):4325-33. PubMed ID: 7876194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
    Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
    J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates.
    Han Y; Da Y; Yu M; Cheng Y; Wang X; Xiong J; Guo G; Li Y; Jiang X; Cai X
    Org Biomol Chem; 2020 May; 18(17):3229-3233. PubMed ID: 32108212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting response to anti-EGFR antibody, cetuximab, therapy by monitoring receptor internalization and degradation.
    Sung Y; Hong ST; Jang M; Kim ES; Kim C; Jung Y; Youn I; Chan Kwon I; Cho SW; Ryu JH
    Biomaterials; 2023 Dec; 303():122382. PubMed ID: 37977005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
    Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New trend in ligand-induced EGFR trafficking: A dual-mode clathrin-mediated endocytosis model.
    Zhou Y; Sakurai H
    J Proteomics; 2022 Mar; 255():104503. PubMed ID: 35093568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab.
    Bhola NE; Thomas SM; Freilino M; Joyce S; Sahu A; Maxwell J; Argiris A; Seethala R; Grandis JR
    Clin Cancer Res; 2011 Aug; 17(15):4996-5004. PubMed ID: 21653688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the Sensitivity of Antibody-Drug Conjugate Efficacy to the Selection of Payload, Antibody, and Cell line.
    Rao M; Murali S; Amores D; Yu F; Tsourkas A
    Bioconjug Chem; 2024 Jan; 35(1):115-124. PubMed ID: 38173338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.
    Yip WL; Weyergang A; Berg K; Tønnesen HH; Selbo PK
    Mol Pharm; 2007; 4(2):241-51. PubMed ID: 17263556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.
    Cassell A; Grandis JR
    Expert Opin Investig Drugs; 2010 Jun; 19(6):709-22. PubMed ID: 20415598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization.
    Vergarajauregui S; San Miguel A; Puertollano R
    Traffic; 2006 Jun; 7(6):686-98. PubMed ID: 16683917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy.
    Bedi A; Chang X; Noonan K; Pham V; Bedi R; Fertig EJ; Considine M; Califano JA; Borrello I; Chung CH; Sidransky D; Ravi R
    Mol Cancer Ther; 2012 Nov; 11(11):2429-39. PubMed ID: 22927667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR binding Fc domain-drug conjugates: stable and highly potent cytotoxic molecules mediate selective cell killing.
    Jäger S; Dickgiesser S; Tonillo J; Hecht S; Kolmar H; Schröter C
    Biol Chem; 2022 Apr; 403(5-6):525-534. PubMed ID: 34535048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
    Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
    Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.